Akagera Medicines, Inc.

Celator Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc.

Suresh K Tipparaju

Dmitri B Kirpotin

Daryl C Drummond

Alexander Koshkaryev

Charles Noble

Bolin Geng

Ozan Alkan

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)

Growing community of inventors

Arlington, MA, United States of America

Suresh K Tipparaju